The discovery and development of antiretroviral agents for the treatment of HIV/AIDS has changed the prognosis of infection from a death sentence to a manageable chronic disease, and represents one of the most miraculous accomplishments in science and medicine over the past three decades. There are now over thirty drugs and drug combinations available for physicians to build an appropriate regimen to battle the virus in the context of needing life-long therapy. All of these drugs need to be dosed daily or more frequently and with one exception all are oral formulations. In the context of chronic daily therapy, patients are challenged with needing to be highly adherent to taking their medicines as well as burdened with a daily reminder of their underlying disease. Our group has been thinking beyond the one pill once a day mantra that has driven the current standard of care options and setting a new objective of designing treatment options that require infrequent dosing in the realm of once a month or less. This presentation will cover the discovery and preclinical development of new antiretroviral agents from our laboratories as well as the evolution of this new area of HIV research.

Long acting HIV antiretroviral agents: Moving beyond one pill once a day

254th National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.